Login
Business
Entertainment
World
Health
Environment
Lifestyle
National
Science
Sports
World
Movies
Web Series
Technology
Cricket
Coronavirus
Auto
Ajab Ghazab
Finance
India
International
Religious
Politics
Home Articles Biocon Biologics
Biocon Biologics appoints Shreehas Tambe as MD, CEO \
2 min read
\
\

Biocon Biologics appoints Shreehas Tambe as MD, CEO

 06-Dec-2022
Tambe takes over from Arun Chandavarkar, who will continue to serve as a non-executive, non-independent director on the board of Biocon Biologics.
06-Dec-2022 Business
\
Biocon Biologics completes acquisition of Viatris’ Global Biosimilars Business \
11 min read
\
\

Biocon Biologics completes acquisition of Viatris’ Global Biosimilars Business

 30-Nov-2022
Bengaluru (Karnataka) [India], November 30 (ANI/PRNewswire): Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523) (NSE: BIOCON), announced today that it has successfully completed its multi-billion-dollar (USD) acquisition of the global biosimilars business of its partner Viatris Inc. (NASDAQ: VTRS).
30-Nov-2022 Business
\
Biocon subsidiary completes acquisition of Viatris for USD 3 billion \
4 min read
\
\

Biocon subsidiary completes acquisition of Viatris for USD 3 billion

 29-Nov-2022
According to a statement by the pharma company, Biocon Biologics and Viatris have obtained all applicable approvals from key global regulators including the US Federal Trade Commission, the Competition Commission of India and the Reserve Bank of India, and its investors, respectively.
29-Nov-2022 World
\
Biocon Biologics to acquire Viatris’ Biosimilars Assets for up to USD 3.335 billion in stock and cash \
4 min read
\
\

Biocon Biologics to acquire Viatris’ Biosimilars Assets for up to USD 3.335 billion in stock and cash

 01-Mar-2022
Bengaluru (Karnataka) [India], March 1 (ANI/PR Newswire): Biocon Biologics Ltd, a subsidiary of Biocon Ltd (BSE code: 532523) (NSE: BIOCON), has entered into a definitive agreement with its partner Viatris Inc. (NASDAQ: VTRS). Accordingly, Biocon Biologics Ltd (BBL) will acquire Viatris' biosimilars business to create a unique fully integrated global biosimilars enterprise.
01-Mar-2022 Business
\
SII announces strategic partnership with Biocon Biologics \
3 min read
\
\

SII announces strategic partnership with Biocon Biologics

 17-Sep-2021
New Delhi [India], September 17 (ANI): Hoping to strengthen India's position as a global vaccine and biologics manufacturing powerhouse, COVID-19 vaccine Covishield maker Serum Institute of India (SII) announced a strategic alliance with biopharmaceutical company Biocon Biologics Limited (BBL).
17-Sep-2021 National
\
Biocon Biologics, Serum Institute Life Sciences enter strategic alliance \
3 min read
\
\

Biocon Biologics, Serum Institute Life Sciences enter strategic alliance

 17-Sep-2021
Bengaluru (Karnataka) [India], Sep 17 (ANI): Biocon Biologics Ltd (BBL) and Serum Institute Life Sciences (SILS) have announced a strategic alliance in a bid to make a significant impact on global healthcare through vaccines and biologics.
17-Sep-2021 Business
\
Biocon Biologics to offer 15 pc stake to Serum Institute Life Sciences at valuation of USD 4.9 billion \
3 min read
\
\

Biocon Biologics to offer 15 pc stake to Serum Institute Life Sciences at valuation of USD 4.9 billion

 17-Sep-2021
Bengaluru (Karnataka) [India], September 17 (ANI): Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd. and Serum Institute Life Sciences Private Limited (SILS) announced a strategic alliance on Thursday and BBL said it will offer around 15 per cent stake to SILS at a post-money valuation of about USD 4.9 billion.
17-Sep-2021 National
\